Torben Sorensen new CEO at curasan AG
Torben Sorensen new CEO at curasan AG
Kleinostheim, September 12, 2019 - The supervisory board of curasan AG (DE000A2YPGM4) today has resolved to appoint Mr. Torben Sorensen as the new CEO of the company as of September 16, 2019 until the end of 31 December 2020.
Torben Sorensen will succeed Michael Schlenk, whose contract anyway expires on September 30, 2019, and whose request for early resignation effective as of the end of September 15, 2019 has been accepted by the Supervisory Board today as well.
Torben Sorensen is a Danish citizen currently living and working in Switzerland. He has been a successful, internationally active interim manager for more than 15 years and has reputation as a turnaround specialist in high-tech companies. Torben Sorensen is also active as a venture capital manager and was CEO of a successful dental med-tech company in Sweden
Today's resolutions of the supervisory board were made in its new assembly with Dr. Kurt Berger, Vienna. Dr. Berger is a self-employed lawyer and was appointed by the court as of September 1, 2019 as the successor of Dr. Tomas Kahn, who has resigned from office.
"After an application process with several candidates, the Supervisory Board unanimously decided in favor of Torben Sorensen based on his professional and personal skills", explains Dr. Detlef Wilke, Chairman of the Supervisory Board. "We are convinced that Torben Sorensen has best qualifications to lead the company into a positive operative direction, and to successfully implement a strategic realignment," added Detlef Wilke. "We are delighted that Torben Sorensen is taking on this responsible position and look forward to working together with great confidence."
The leaving CEO Michael Schlenk welcomes the supervisory board's decision and comments:"In my view the supervisory board made a good choice. I wish Torben Sorensen every success in his challenging new task and some good luck to lead the company and its employees into a profitable future!"
Contact curasan AG: Andrea Weidner Investor Relations & Corporate Communications +49 6027 40 firstname.lastname@example.org
About curasan AG: curasan develops, manufactures and markets biomaterials and medical devices in the field of bone and tissue regeneration, wound healing and osteoarthritis therapy. As a pioneer and global technology leader in the growing field of regenerative medicine, curasan is specialized primarily on biomimetic bone grafting materials for dental, oral/maxillofacial, orthopedic and spinal applications, i.e. materials mimicking biological structures. Numerous patents and a broad record of scientific publications demonstrate the clinical success of the products and the highly innovative strength of curasan. Dental and orthopaedic clinicians worldwide benefit from the broad range of the premium quality and easy to use portfolio offered by the technology leader curasan. curasan maintains its own high-tech facilities for research, development and manufacturing of biomaterials in Frankfurt/Main, Germany. In addition to its headquarters, the company has a subsidiary, curasan, Inc., in Wake Forest, near Raleigh, N.C., USA. curasan's innovative products are cleared by the US Food and Drug Administration (FDA) and many other international authorities and available in almost 50 countries worldwide. curasan AG is a public company listed in the General Standard at the Frankfurt Stock Exchange.
12.09.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.deLanguage: English Company: curasan AG Lindigstraße 4 63801 Kleinostheim
Germany Phone: 06027/40 900 0 Fax: 06027/40 900 29 E-mail: email@example.com Internet: www.curasan.de ISIN: DE000A2YPGM4 WKN: A2YPGM Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange EQS News ID: 872729 End of News DGAP News Service